CytoDyn Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Additional Information (Detail)

Subsequent Events - Additional Information (Detail) - USD ($)																	1 Months Ended						2 Months Ended	6 Months Ended
	May 01, 2021	Feb. 01, 2021	Jul. 31, 2020	Jul. 30, 2020	Jul. 29, 2020	Jun. 30, 2020	Jun. 16, 2020	Jun. 10, 2020	Jun. 01, 2020	Jan. 31, 2020	Dec. 23, 2019	Dec. 13, 2019	Dec. 09, 2019	Apr. 05, 2019	Jun. 26, 2018	Jun. 15, 2018	Jul. 27, 2020	Jun. 30, 2020	Apr. 16, 2019	Feb. 13, 2019	Jan. 30, 2019	Nov. 15, 2018	Jul. 31, 2019	Nov. 30, 2019	Jul. 22, 2020	Jul. 16, 2020	Jun. 29, 2020	Jun. 22, 2020	May 31, 2020	Feb. 04, 2020	May 31, 2019	Apr. 30, 2010
Subsequent Event [Line Items]
Class of warrants, exercise price																								$ 0.45
Proceeds from Stock Options Exercised									$ 10,800,000
Common stock per share price																													$ 0.001		$ 0.001
Term of warrants														5 years
Warrants to purchase common shares, shares																														833,332
Monthly rent payments										$ 9,901
Common stock, shares authorized																													700,000,000		700,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price																			150,000
Proceeds from convertible promissory note																					$ 5,000,000
Common Stock, Shares, Issued																													519,261,580		329,554,763
Note
Subsequent Event [Line Items]
Convertible promissory note principle amount					$ 28,500,000										$ 5,700,000
Proceeds from convertible promissory note					$ 25,000,000										$ 5,000,000
Common stock conversion price															$ 0.55							$ 0.55
Convertible Promisssory Notes [Member]
Subsequent Event [Line Items]
Outstanding balance of convertible note including accrued unpaid interest																	$ 9,537,500
Maximum [Member]
Subsequent Event [Line Items]
Long-term purchase commitment.								$ 103,000,000
Purchase price, per share						$ 1.35												$ 1.35
Minimum [Member]
Subsequent Event [Line Items]
Long-term purchase commitment.								$ 60,000,000
Purchase price, per share						$ 0.35												$ 0.35
Subscription Agreement [Member]
Subsequent Event [Line Items]
Class of warrants, exercise price																$ 0.75								$ 0.45
Stock issued during period											14,754,098	2,433,333	2,568,330	10,931,000		1,970,000				10,728,480				19,100,333
Term of warrants																5 years								5 years
Warrants to purchase common shares, shares																1,970,000								11,987,250
Number of shares to be sold																										105,000
Purchase price, per share											$ 0.305	$ 0.30	$ 0.30	$ 0.50		$ 0.50				$ 0.50
Proceeds from Issuance of Common Stock											$ 4,500,000					$ 900,000								$ 6,300,000
Subscription Agreement [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Purchase price, per share																								$ 0.40
Subscription Agreement [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Purchase price, per share																								$ 0.30
Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Common stock, shares authorized																																100,000,000
Subsequent Event
Subsequent Event [Line Items]
Class of warrants, exercise price							$ 0.45
Stock issued during period									24,130,630
Stock options with an exercise prices									$ 1.35
Stock options with an exercise prices									$ 0.30
Common stock per share price																									$ 0.001
Term of warrants																												5 years
Warrants to purchase common shares, shares							105,000
Monthly rent payments	$ 13,670	$ 13,012
Vesting period							5 years
Discount on convertible promissory note			$ 3,400,000
Expense payable on issuance of convertible promissory note			$ 100,000
Common Stock, Shares, Issued																											4,000,000
Subsequent Event \| Stock Compensation Plan [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price						640,000
Subsequent Event \| Convertible Promisssory Notes [Member]
Subsequent Event [Line Items]
Common stock conversion price																	$ 4.50
Shares issued on conversion																	2,119,444
Subsequent Event \| Maximum [Member]
Subsequent Event [Line Items]
Common stock, shares authorized																									800,000,000
Subsequent Event \| Maximum [Member] \| Stock Compensation Plan [Member]
Subsequent Event [Line Items]
Stock option granted, exercise price			$ 6.15
Subsequent Event \| Minimum [Member]
Subsequent Event [Line Items]
Common stock, shares authorized																									700,000,000
Subsequent Event \| Minimum [Member] \| Stock Compensation Plan [Member]
Subsequent Event [Line Items]
Stock option granted, exercise price			$ 3.12
Subsequent Event \| Nader Pourhassan [Member]
Subsequent Event [Line Items]
Common Stock, Shares, Issued			323,157
Shares paid for tax witholding For Share Based Compensation			156,570
Subsequent Event \| Series B Convertible Preferred Stock
Subsequent Event [Line Items]
Aggregate dividend paid in cash				$ 243,000
Subsequent Event \| Warrants
Subsequent Event [Line Items]
Stock issued during period																		24,853,675
Public Warrant Tender Offerings [Member]
Subsequent Event [Line Items]
Stock issued during period																		16,543,539					45,375,923
Common stock per share price																							$ 0.001
Proceeds from Issuance of Common Stock																		$ 7,800,000					$ 11,900,000
Public Warrant Tender Offerings [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Purchase price, per share						$ 0.95												$ 0.95					$ 0.40
Public Warrant Tender Offerings [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Purchase price, per share						$ 0.21												$ 0.21					$ 0.30